Albumin is a globular protein found in the blood's liquid component called plasma. It is the most abundant protein in plasma, accounting for about 50% of total protein. It plays an important role in maintaining proper intra-tumor pressure of blood and transporting hormones, fatty acids and other compounds throughout the body. It is derived from plasma fractions and is used clinically to treat a wide variety of diseases. Other types of albumin are used clinically. These include human serum albumin, bovine serum albumin and recombinant albumin.

Factors leading to the growth of the albumin market include life-threatening diseases and conditions such as surgical procedures, liver disease, trauma and burns. In addition, there is an increase in awareness of recombinant albumin products, a surge in demand for albumin products, and an increase in the non-therapeutic use of albumin, accelerating market growth. However, stringent government regulations and reforms and the risk of side effects after using albumin products hinder market growth. Conversely, the large-scale production of albumin and the development of cost-effective therapies along with the presence of undeveloped markets in emerging economies are expected to provide favorable growth opportunities for the market.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/2583



Top Leading Manufactures:
• Grifols S.A.
• Octapharma AG
• China Biologic Products Inc.
• Shire Plc
• Ventria Bioscience
• CSL Limited
• Albumedix Ltd.
• Merck KGaA
• Thermo Fisher Scientific
• Baxter International Inc.

Human serum albumin has a high blood flow, is highly applicable to the treatment of various diseases, and the production of human serum albumin has improved due to the emergence of advanced technologies, and it accounted for the largest proportion in 2016. However, recombinant albumin is expected to grow at a high CAGR from 2017 to 2023.
The utilization rate of albumin for therapeutics is high owing to rise in prevalence of trauma and cases of burns as well as increase in the number of surgical procedures. However, drug formulation and vaccines segment is expected to grow at a high CAGR during the forecast period.

Make an Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2583


Key Findings of the Albumin Market:
• The bovine serum albumin segment accounted for nearly one-eighth share of the global albumin market in 2016.
• The recombinant albumin segment is expected to grow at highest CAGR from 2017 to 2023.
• The component of media segment accounted for around one-fifth share of the global market in 2016.
• Europe accounted for around one-third share of the global market in 2016.
• LAMEA is expected to provide lucrative market growth opportunities from 2017 to 2023.
North America was the leading revenue contributor to the global albumin market in 2016, and is expected to dominate the market during the forecast period. This is attributed to the early approval of albumin products and high adoption of recombinant albumin in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward albumin products.

Access Full Summery @ https://www.alliedmarketresearch.com/human-albumin-market